*Actual product packaging may differ from the image shown.
Tesamorelin (Injectable)
Shop All Treatments
Tesamorelin: Daily Injection for Visceral Fat Reduction and Body Composition
An FDA-approved growth hormone-releasing peptide best known for reducing the deepest, most metabolically active belly fat.
Tesamorelin is a synthetic growth hormone-releasing hormone analog, FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. It’s now widely prescribed off-label by longevity-focused physicians for adults with elevated visceral fat (the metabolically active fat deep in the abdomen) and the metabolic risks that come with it. Tesamorelin is among the most studied of the GHRH-class peptides for body composition outcomes specifically.
Physician-prescribed · FDA-approved active · Compounded by licensed US pharmacies · Ongoing care team support
Tesamorelin (Growth Hormone-Releasing Hormone Analog): Tesamorelin is a stabilized analog of growth hormone-releasing hormone that prompts your pituitary to release growth hormone in a more potent and sustained way than sermorelin. The downstream rise in IGF-1 supports the breakdown of visceral fat in particular, with clinical trials showing 15 to 18% reduction in visceral adipose tissue at 26 weeks of therapy.
Best for: Adults with elevated visceral fat and the metabolic markers that come with it (elevated waist circumference, fatty liver, insulin resistance), particularly when other approaches haven’t reduced central fat distribution.
Not recommended for: Anyone with active malignancy, pituitary disease or recent pituitary surgery, severe hyperglycemia, pregnancy or breastfeeding. Your provider reviews your full medical history before prescribing.
Most common side effects are injection site reactions, joint stiffness or pain, mild swelling in the extremities, and headache. More notable considerations include increases in blood glucose and the same general cautions as other GHRH analogs (not appropriate during active cancer).
¹ 15.2% reduction in visceral adipose tissue over 26 weeks (pivotal trial) Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine, 2007;357(23):2359-2370. (15.2% reduction in visceral adipose tissue at week 26 vs 5% with placebo.) → NEJM · PubMed
² IGF-1 increased by about 81% over 26 weeks (pivotal trial) Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials. JCEM, 2010;95(9):4291-4304. (Mean IGF-1 increases of ~80 to 100 ng/mL during 26-week therapy.) → PubMed
³ Triglycerides fell by about 50 mg/dL in the pivotal trial Falutz J, et al. (2010 pooled analysis, same as ²). (Reductions in triglycerides and improvements in some lipid parameters in HIV-lipodystrophy patients.) → PubMed
How it Works With EHRX
The entire process is online. No waiting rooms. Just straightforward, medically guided care.
Step 1
Choose your treatment and complete checkout
You'll receive a confirmation email with next steps.
Step 2
Complete a brief medical consultation
Check your email for a link to a short intake form and link to a virtual consult with a licensed physician.
Step 3
A licensed provider reviews your consultation
If approved, your prescription is written and sent to the pharmacy. If not, you receive a full refund.
Step 4
Your pharmacy ships within 3–5 business days
Your medication is shipped directly to your door in temperature-controlled packaging.
What to know before you start.
Tesamorelin (Injectable) is a compounded medication prepared by a licensed pharmacy for individual patient use.
It has not been reviewed by the FDA for safety or efficacy, and is prescribed based on the clinical judgment of a qualified healthcare provider. Compounded drugs are permitted to be prescribed but are not FDA-approved for safety and efficacy.
Clinical Evidence
In FDA registrational trials, tesamorelin reduced visceral adipose tissue by 15 to 18% over 26 weeks in adults with lipodystrophy, with associated improvements in triglycerides and waist circumference. (Source: Falutz et al., New England Journal of Medicine, 2007)
Frequently Asked Questions
We aim to provide absolute clarity regarding your biological data and personalized wellness protocols.
Daily subcutaneous injection, typically in the morning or evening on a consistent schedule.
Tesamorelin is a more stabilized GHRH analog with a stronger effect on visceral fat reduction in clinical trials. Sermorelin works through the same pathway but with milder pharmacokinetics.
Body composition effects typically appear over 3 to 6 months of consistent use. Visceral fat reduction is best measured by waist circumference or imaging.
Yes. Baseline IGF-1, fasting glucose, HbA1c, and a metabolic panel are needed to establish your starting point and rule out contraindications.
You won’t be charged for the medication.
Coverage exists for the FDA-approved indication (HIV-associated lipodystrophy) but not for off-label use, which is paid out of pocket.
Yes, at any time before your next shipment, with no long-term commitment.
Labs at 8 to 12 weeks initially, with ongoing check-ins at a recurring cadence.
Yes. Tesamorelin can raise blood glucose. Your provider monitors HbA1c and may adjust the protocol if needed.
The next generation
of weight management.
Dual-incretin metabolic support — personalized to you.
